CRISPR Therapeutics AG (CRSP)
Automate Your Wheel Strategy on CRSP
With Tiblio's Option Bot, you can configure your own wheel strategy including CRSP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRSP
- Rev/Share 0.4203
- Book/Share 21.2845
- PB 1.705
- Debt/Equity 0.1199
- CurrentRatio 15.6355
- ROIC -0.2322
- MktCap 3134138673.0
- FreeCF/Share -3.5823
- PFCF -10.1804
- PE -8.0868
- Debt/Assets 0.1013
- DivYield 0
- ROE -0.2008
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRSP | Evercore ISI | In-line | Outperform | $60 | $99 | Feb. 14, 2025 |
| Upgrade | CRSP | TD Cowen | Sell | Hold | -- | $35 | Feb. 12, 2025 |
| Initiation | CRSP | H.C. Wainwright | -- | Buy | -- | $65 | Feb. 3, 2025 |
News
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
Read More
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Published: May 16, 2025 by: MarketBeat
Sentiment: Positive
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been slow due to its high cost, specialized centers, and lengthy required preconditioning. Still, CRSP will eventually receive 40% of Casgevy's profits through its partnership with VRTX.
Read More
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Negative
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals, impacting CRISPR's gene and cell therapy timelines.
Read More
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates.
Read More
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
2 Beaten-Down Stocks With Incredible Upside Potential
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
Read More
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Read More
CRISPR Therapeutics Set To Reach Previous Heights
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently sitting at historical support, at a valuation that is clinical assets are expected to drive shareholder value back to previous highs. We are bullish on CRISPR, rating it a buy with a $70 price target, as the stock currently sits at a strong support level of $40.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Neutral
CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Welcome again to TD Cowen's 45th Annual Healthcare Conference, our first day.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Published: February 28, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
Read More
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- …
Read More
About CRISPR Therapeutics AG (CRSP)
- IPO Date 2016-10-19
- Website https://www.crisprtx.com
- Industry Biotechnology
- CEO Dr. Samarth Kulkarni Ph.D.
- Employees 393